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Manuscript receis widely accepted that diabetes mellitus (DM) impairs endothelial nitric oxide synthase activity as well as
enhances the production of reactive oxygen species, thus resulting in diminished nitric oxide bioavailability and the
consequent pro-atherogenetic alterations. Important biomarkers of the vasculature are related to endothelial
dysfunction, to inﬂammatory and coagulation processes, and to oxidative stress in DM. Several therapeutic
strategies might exert favorable effects on the vasculature of diabetic patients, such as insulin analogues,
antihypertensive agents, statins, and hypoglycemic agents, whereas in spite of the prominent role of oxidative stress
in diabetes, antioxidant therapy remains controversial. The use of speciﬁc biomarkers related to vascular function
could be a useful therapeutic approach in such patients. (J Am Coll Cardiol 2013;62:667–76) ª 2013 by the
American College of Cardiology FoundationIt is well known that diabetes mellitus (DM) is a meta-
bolic disorder characterized by increased mortality rates and
importantly implicated in the atherogenetic process (1).
Hyperglycemia, insulin resistance, hyperinsulinemia, hyper-
lipidemia, and hyperhomocysteinemia represent important
pathophysiological components of DM that result in en-
dothelial/vascular dysfunction through several underlying
processes (2).
It is widely accepted that DM impairs endothelial nitric
oxide synthase (eNOS) activity as well as enhances the
production of reactive oxygen species (ROS), thus resulting
in diminished nitric oxide (NO) bioavailability and the
consequent pro-atherogenetic alterations (3). Moreover, di-
abetic subjects exhibit pathologically enhanced biomarkers
of endothelial function, such as vascular cell adhesion
molecule (VCAM)-1 and von Willebrand factor (vWF),
and markers of systemic inﬂammation including C-reactive
protein (CRP) and tumor necrosis factor (TNF)-a (4).
Additionally, intrinsic properties of the injured endothelium
result in vasoconstriction, smooth cell proliferation, coagu-
lation disorders, leukocyte aggregation, thrombosis, and
vascular inﬂammation predisposing to atherosclerosis (3).
In the present article, we review the pathophysiological
role of DM in vascular dysfunction, focusing on the major
novel biomarkers and brieﬂy reviewing the current effective
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It is well established that endothelium is not just a single
layer but rather a regulator exerting signiﬁcant autocrine,
paracrine, and endocrine actions and affecting several cell
types. In addition, endothelium regulates the vascular tone
via several vasoactive mediators and primarily NO. However,
these functions are altered in states of DM (Fig. 1, Table 1).
Hyperglycemia, insulin resistance, and elevated free fatty
acids (FFAs) trigger systemic inﬂammation and impair NO
bioavailability (5), leading to impaired endothelial function.
Insulin is a normal regulator of eNOS activation and NO
production through successive phosphorylation. More
speciﬁcally, insulin stimulates phosphatidylinositol 3–kinase/
Akt pathway, which enhances eNOS activation and subse-
quent NO production. Insulin resistance in DM attenuates
this pathophysiological process and suppresses the normal
NO secretion (6). Furthermore, within the pathophysio-
logical alterations of DM, FFAs are typically elevated.
Consequently, NO bioavailability is further impaired,
whereas oxidized low-density lipoprotein (oxLDL) forma-
tion is enhanced. Recent data support the implication of
tetrahydrobiopterin (BH4) and asymmetric dimethylargi-
nine (ADMA) in diabetic atherosclerosis (7).
Equally important, endothelial progenitor cells (EPCs)
are likely implicated in diabetic vasculopathy. Endothelial
progenitor cells are stem cells enrolled to repair any damage to
endothelium. Clinical and experimental studies conclude that
DM impairs quantity and quality of EPCs; thus there is
a blunted response to vascular injury, and in this sense they
propose cell-based therapy as a novel approach to patients
with DM.
Abbreviations
and Acronyms
ADMA = asymmetric
dimethylarginine
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CAD = coronary artery
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FMD = ﬂow-mediated
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siological alterations ofDMdamage
endothelial integrity through
inﬂammatory and oxidative pro-
cesses (Fig. 2). Systemic inﬂam-
mation results in migration of
leukocytes into the vessel wall and
in increased secretion of cyto-
kines. Elevated levels of cir-
culating cytokines causedamong
other changesdenhanced oxLDL
effected by scavenger macrophages
and results in foam cell formation,
which is critical in the atheroscle-
rotic process, especially in DM.
Circulating Biomarkers
Associated With Vascular
Dysfunction in DM
Inﬂammatory biomarkers. Cha-
nges in the expression of adhesion
molecules, pro-inﬂammatorymol-
ecules, and alterations in their
regulation exist in states of DM
(Table 1). The activated endothe-
lium expresses adhesion molecules
and other factors that participate in
the inﬂammatory process and,
consequently, in the pathophysi-
ology of atherosclerosis in DM.
Vascular endothelium is not only
affectedbut also contributes through
these processes. Thus, endothelial
cells can be stimulated by pro-
inﬂammatory molecules such as
TNF-a and CRP to promote an
atherogenic phenotype (8). The
main inﬂammatory markers that
are used and have been proved to
provide prognostic information on
the outcomeandprogressionof thedisease indiabetic patients areCRP,TNF-a, interleukin (IL)-6
intercellular adhesion molecule (ICAM)-1, and VCAM-1.
CRP. C-reactive protein is the most commonly used inﬂam-
matory biomarker. In addition to its role as an important
inﬂammatory marker, it can exert modulatory effects through
its presence in atherosclerotic plaques (9). C-reactive protein
is an acute-phase protein, and its expression is mainly regu-
lated by IL-6 during the acute phase with both a causative role
of DM and a role associated with the risk of DM complica-
tions.More speciﬁcally, increased CRP levels are independent
predictors of type 2 diabetes mellitus (T2D) in apparently
healthy women, supporting the hypothesis that subclinical
inﬂammation is an underlying factor in the pathogenesis of
T2D (10). Beyond DM development, CRP predicts theoutcomes in diabetic patients with cardiovascular disease.
Decreased CRP levels might serve as a major predictor of
successful percutaneous transluminal angioplasty outcome in
diabetic patients (11), whereas high-sensitivity C-reactive
protein (hsCRP) has been proven to be useful in predicting
adverse cardiac outcomes (12). Given that inﬂammation plays
a crucial role in restenosis, Paiva et al. (13) demonstrated also
that diabetic patients exhibit higher pre-procedural levels of
CRP and revealed a further exacerbated inﬂammatory
response after intervention. According to data derived from
the Munich Myocardial Infarction Registry (14) in diabetic
patients, both a CRP level>7 mg/l and a glomerular ﬁltration
rate <60 ml/min were independent risk factors for mortality
(14). Although several studies have debated the prognostic
role of CRP, the relation of CRP and DM might be more
complex, as previously described (15). Thus, the prognostic
role of CRP after MI in diabetic patients seems to be reduced,
suggesting that the burden of risk factors associated with DM
might blunt the prognostic role of CRP. Recently, novel
factors including genetics have made this association more
complex (16).
PRO-INFLAMMATORY CYTOKINES. Other inﬂammatory mole-
cules, such as pro-inﬂammatory and anti-inﬂammatory
cytokines, have been evaluated or are still under investiga-
tion. Important cytokines participating in atherogenesis are
IL-6 and TNF-a, with a role that is mainly associated with
the risk of DM complications. Activation of inﬂammatory
processes in DMdmainly on the basis of the increased levels
of CRP, ﬁbrinogen, IL- 6, IL-1, and TNF-admight lead in
alterations of vaso-regulatory responses, leukocyte adhesion
to endothelium, and facilitation of pro-coagulant activity.
A case-control study, within the prospective population-
based EPIC (European Prospective Investigation into
Cancer and Nutrition)-Potsdam study (17), has demon-
strated that the pattern of circulating inﬂammatory cyto-
kines modiﬁes the risk for T2D. A combined elevation of
IL-1beta and IL-6 was independently associated with
increased risk of T2D, suggesting that subclinical inﬂam-
matory process has a role in the pathogenesis of T2D. In
a cross-sectional study of youth with and without type 1
DM, inﬂammatory markers were evaluated as potential
contributors to accelerated atherosclerosis. Patients exhibi-
ted higher IL-6 and ﬁbrinogen levels, independent of
adiposity and glycemic control, whereas hsCRP levels were
signiﬁcantly higher in patients of the top 3 quartiles of
glycated hemoglobin and among normal-weight subjects
(18). Furthermore, after percutaneous coronary interven-
tion, IL-6 was signiﬁcantly increased in diabetic persons
with peri-interventional hyperglycemic state and inversely
correlated with responsiveness to clopidogrel and aspirin
(19). Moreover, DM patients showed higher platelet
reactivity after a 600-mg clopidogrel loading dose
(compared with non-DM), and the observed increase in
platelet reactivity was mainly due to a higher platelet
aggregation in individuals with poor metabolic control.
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Figure 1 Diabetes-Related Factors Leading to Its Complications
Insulin resistance, hyperglycemia, obesity, dyslipidemia, and hypertension are states that accompany diabetes mellitus. Through several complex pathophysiological pathways,
such factors are capable of impairing endothelial function, increase inﬂammatory process, and alter the pro-coagulant state. CRP ¼ C-reactive protein; ICAM ¼ intercellular
adhesion molecule; IL ¼ interleukin; PAI ¼ plasminogen activator inhibitor; TNF ¼ tumor necrosis factor; VCAM ¼ vascular cell adhesion molecule; vWF ¼ von Willebrand factor.
JACC Vol. 62, No. 8, 2013 Tousoulis et al.
August 20, 2013:667–76 Vascular Function and Diabetes
669Diabetes mellitus was also a strong predictor of post-
treatment platelet reactivity (multivariable analysis),
whereas after analysis of interindividual time dependency of
platelet reactivity, the platelet inhibition by antiplatelet
treatment was mitigated in DM patients compared with
non-DM. Of note, in the ﬁeld of pro-inﬂammatory cyto-
kines, among end-stage renal disease patients due to DM,
elevated IL-6 levels have strong predictive value for poorTable 1 Mechanisms and Markers of DM-Related En
Mechanisms Biomarkers
ICAM-1
VCAM-1
IL-1-IL-6
Insulin resistance TNF-a
Abnormal cluster of hyperglycemia MCP-1
Increased oxidative stress/
reduced nitric oxide production
Selectins (E-sele
Growth factors
Increased inﬂammatory status (VEGF)
Elevated free fatty acids ET-1
Glycosylated-end products PAI-1
Vascular smooth muscle cell dysfunction Fibrinogen
Endothelial dysfunction vWF
Glucose levels
Insulin resistanc
HbA1c
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ADMA
Homocysteine
ADMA¼ asymmetrical dimethylarginine; EPC¼ endothelial progenitor cell; ET¼ enth
molecule; IL ¼ interleukin; MCP ¼ monocyte chemoattractant protein; PAI ¼ plasm
adhesion molecule; VEGF ¼ vascular endothelial growth factors; vWF¼ von Willebroutcome (20). With regard to the treatment of DM, it has
been demonstrated to alter inﬂammatory cytokines. This is
nicely exempliﬁed by insulin treatment in T2D patients,
which has been shown to affect the expression of IL-6 and
subsequently to modify the thrombotic mechanisms in
patients with coronary atherosclerosis, independent of the
duration of diabetes and extent of coronary artery disease
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Figure 2 Critical Role of Hyperglycemia in Atherogenesis
Hyperglycemia plays a central role in states of diabetes mellitus. Pathways triggered by advanced glycated end products and mediated by the nuclear factor (Nf)-kB lead to
increased oxidative status and thus to impaired nitric oxide (NO) production/bioavailability. As a result, numerous substances are increased, such as growth factors, cytokines,
pro-coagulant factors, and others strongly related to altered underlying processes that induce and promote atherogenesis. AGE ¼ advanced glycated end product; NAD(P)H ¼
nicotinamide adenine dinucleotide phosphate; ROS ¼ reactive oxygen species; EPC ¼ endothelial progenitor cell; BH4 ¼ tetrahydrobiopterin.
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670Tumor necrosis factor-a has a primary role in the regu-
lation of immune cells; however, it represents a pleiotropic
inﬂammatory cytokine, because it has been widely studied for
its pathogenic role in disease. Increased levels of TNF-a have
been found in acute and chronic inﬂammatory conditions in
which a shift toward a pro-atherogenic lipid proﬁle and
impaired glucose tolerance occurs. It has been demonstrated
that admission hyperglycemia is related to increased serum
concentrations of IL-6 reduced ex vivo production of TNF-
a and is associated with increased intensive care unit
mortality rate in a medical intensive care unit (22).
Furthermore, TNF-a levels were elevated in patients with
T2D, according to a cross-sectional study. Also, TNF-
a concentrations and brachial artery diameter were negatively
correlated with ﬂow-mediated dilation (FMD) and remained
signiﬁcantly associated with FMD after adjustment for
group, age, and body mass index (23).
ADHESION MOLECULES. In the presence of risk factors such
as DM, the endothelium can be activated and expresses
VCAM-1 and ICAM-1, important mediators for the
adhesion of leukocytes to the endothelial surface and
signiﬁcantly related to the risk of DM complications. In
a large prospective, nested case-control study within the
Nurses’ Health Study (24), including women with DM,
baseline median levels of the biomarkers of endothelial
dysfunction were signiﬁcantly higher among cases than
among control subjects. Moreover, elevated E-selectin and
ICAM-1 levels predicted incident of diabetes in logistic
regression models after adjustment for several risk factors.However, in patients with and without diabetes presenting
with unstable angina and non–Q-wave myocardial infarction
there was no signiﬁcant difference in levels of soluble
ICAM-1 and VCAM-1 between diabetic and non-diabetic
patients (25).
Coagulation-related biomarkers. Diabetes mellitus is
associated with alterations in the balance of pro-thrombotic
and anti-ﬁbrinolytic state, and several molecules such as
plasminogen activator inhibitor (PAI)-1, tissue factor, and
vWF could reasonably serve as markers of endothelial
function. Both endothelial cells and macrophages contribute
to the generation of altered coagulation processes via
increased expression of PAI-1, tissue factor, platelet activa-
tion, and acute phase reactions that increase levels of coag-
ulation factors such as ﬁbrinogen. It is worth mentioning
that pro-thrombotic molecules such as PAI-1, vWF, and
ﬁbrinogen are produced under cytokine stimulation and
therefore can be considered as products of the acute phase
response, whereas current knowledge indicates that they are
associated with the risk of DM complications. It is very
important to highlight that acute phase reactions are
a generalized inﬂammatory response to stimuli and not
speciﬁc products. In the Insulin Resistance Atherosclerosis
Study (26) subjects with diabetes at follow-up had higher
baseline levels of ﬁbrinogen as well as of CRP and PAI-1
than control subjects. Notably, PAI-1 levels have predicted
T2D, independent of insulin resistance. Additionally,
Yngen et al. (27) indicated that patients with type 1 DM
and microangiopathy had remarkably elevated CRP and
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671E-selectin levels, whereas vWF levels did not vary between
the contrasting populations. In patients with micro-
angiopathy, thrombin-induced platelet P-selectin expression
was enhanced and soluble P-selectin and soluble CD40
ligand concentrations were increased compared with the
control subjects, whereas all 3 parameters were similar in
patients without microangiopathy and in the control
subjects. Notably, in a 9-year observational study of T2D, it
has been demonstrated that vWF, E-selectin, CRP, tissue
plasminogen activator, and ﬁbrinogen are independent
predictors of progression of microalbuminuria and mortality
(28).
Oxidative stress biomarkers. Increased oxidative stress
(associatedwith the complications ofDM) in the vasculature is
a major contributor of endothelial dysfunction in DM via the
superoxide production and impairment of NO bioavailability
in the vascular wall. Hohenstein et al. (29) examined eNOS
expression in patients with diabetic nephropathy and noticed
a strong correlation between eNOS activity and degree of
proteinuria, which is indicative of glomerular endothelium
function, thereby supporting the importance of increased
oxidative stress as a mechanism of endothelial dysfunction in
DM. Also, it has been demonstrated that circulating markers
of oxidative stress, including F2 isoprostanes and antibodies
against oxLDL, are increased inhumanswith diabetes, obesity,
and insulin resistance. According to cross-sectional data
derived from the community-based Framingham Offspring
Study (30), across 8-epi-prostaglandin F2alpha/creatinine
tertiles, the prevalence of insulin resistance increased. Thus,
systemic oxidative stress seems to be related to insulin resis-
tance in subjects at average or increased risk of diabetes.
Other circulating biomarkers related to DM. Tetrahy-
drobiopterin is an essential co-factor in the regulation of
eNOS. Reduced synthesis or oxidative inactivation of the
BH4 could also lead to reduced NO availability; thus when
BH4 is limiting, NOS generates oxygen rather than NO
from oxygen and nicotinamide adenine dinucleotide phos-
phate and is potentially related to the risk of DM compli-
cations. Tetrahydrobiopterin plasma levels along with levels
in the vascular wall could reﬂect vascular endothelial health,
given that its levels are vulnerable to acute increases in
plasma glucose and might be affected early in T2D.
Moreover, clinical studies have examined the controver-
sial role of homocysteine in diabetic atherosclerosis and
complications. In a relevant study, hyperhomocysteinemia
was associated with reduced creatinine clearance, potentially
through endothelial dysfunction. Thus, plasma homo-
cysteine might be an intermediate factor in the relationship
between endothelial dysfunction and renal function (31).
The suspected relation between hyperhomocysteinemia and
ADMA should also have been noticed. Higher concentra-
tions of ADMA have been associated with endothelial
dysfunction in several cardiovascular diseases, such as
hypercholesterolemia and CAD (32). This is nicely exem-
pliﬁed by Fard et al. (33), who demonstrated that plasma
ADMA increased after a high-fat meal, and this wasassociated with a decrease in brachial arterial vasodilation
after reactive hyperemia. Despite the promising studies
conducted, recent evidence arising from the use of folates
suggests that the role hyperhomocysteinemia as a risk factor
for cardiovascular disease and DM should be toned down,
although its measurement might be helpful for identifying
subjects at greater risk of disease, who might thus beneﬁt
from a more aggressive treatment of other modiﬁable risk
factors (34). Additionally, hyperhomocysteinemia should
not be underestimated, because it might maintain interest as
a marker of systemic or endothelial oxidant stress (35).
Endothelial progenitor cells are circulating cells mostly
known as mediators of endothelial repair. Several of the
abnormalities associated with insulin resistance, including
reduced NO bioavailability and production of ROS,
potentially interfere with EPC function while exhibiting
a potential role in the risk of DM complications. Thus, T2D
subjects seem to have reduced levels of circulating EPCs
correlated with disease severity, whereas hyperglycemia
might partially explain this association (36).
Recently highlighted biomarkers: micro-ribonucleic acids
and endothelial microparticles. Although several bio-
markers already established for their association with DM
have been used to describe endothelial dysfunction in states of
DM, during the last years, 2 new biomarkers have emerged as
potential challengers of the classical biomarkers (Table 3).
Micro-ribonucleic acids (miRs), a class of approximately
22 nucleotide noncoding ribonucleic acids, are nowadays
considered as signiﬁcant modulators of several processes
(37,38), because they are able to regulate gene expression.
The contribution of miRs to atherogenesis is not fully
evaluated; however, recent research suggests that miRs
dysregulation can lead to endothelial dysfunction. The miRs
exhibit either favorable or suppressive effect on eNOS
activity. Actually, the overexpression of miR21 enhances
NO production but mitigates endothelial cell apoptosis
(39,40). By contrast, miR-221 and miR-222 overexpression
lead to impaired eNOS activity and consequently decreased
NO bioavailability (40). Down-regulation of numerous
miRs (miR-20b, miR-21, and others) has been found in
states of DM, whereas miR-28-3p was found to be
enhanced (41). A combination (according to the authors) of
5 miRs (miR-15a, miR-126, miR-320, miR-223, miR-28-
3p) can be adequate for a nonredundant classiﬁcation.
Furthermore, dysregulation of these miRs enabled the iden-
tiﬁcation of 52% of normoglycemic subjects in developing
DM in a 10-year period. Also, in patients with newly diag-
nosed DM, miR-9, miR-29a, miR-30d, miR-34a, miR-146,
miR-124, and miR-375 were signiﬁcantly higher compared
with subjects with normal glucose tolerance (42). Although
promising, the studies onmiRs have shown a role only inDM
complications, whereas a causative role is still not conﬁrmed.
Not only miRs but also several genetic polymorphisms have
been investigated in terms of DM. Thus, polymorphisms of
molecules such as osteoprotegerin (43) or that of the tran-
scription factor 7-like 2 locus (44) could be used in the
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speciﬁc populations, respectively. Other studies have shown
that genetic polymorphisms of eNOS are associated with the
risk of diabetic neuropathy (45) and hypertension (46),
whereas other eNOS polymorphisms might have a protective
role against diabetic retinopathy (47). Recently, it was
shown that a single nucleotide polymorphism on CRP
gene (A3872G) might affect the duration of and partly the
risk for DM (16). In addition, this polymorphism had
a signiﬁcant impact on CRP levels in patients with T2D
exhibiting CAD.
Closely related to the miRs are the microparticles
(MPs). The latter are shed membrane particles of <1 mm
in diameter thought to be budded into the circulation
from endothelial cells (EMPs) and various blood cells,
including platelets, leukocytes, and erythrocytes (1,2,48,49).
Circulating MPs constitute a heterogeneous population
of different cellular origins, numbers, size, and antigenic
composition. Proposed mechanisms of MP generation
include apoptosis, mechanical injury, and cellular activation
by cytokines (48,49). Microparticles are found in blood
circulation of healthy subjects, and their number is increased
in cardiovascular disease and conditions predisposing to
cardiovascular disease (48,49). The number of MPs, long
considered as functionally inert cell debris, is suggested as
a marker of endothelial damage and platelet activation
(48,49). More recently, it was appreciated that MPs harbor
a number of membrane and cytoplasmic proteins and
therefore could play a role as a disseminated storage pool of
bioactive effectors in intercellular communication mediating
effects in cardiovascular physiology and pathophysiology
(48–51). Moreover, EMPs are also implicated in the traf-
ﬁcking of messenger ribonucleic acid and proteins between
cells. Interestingly, EMPs contain nuclear acid material such
as deoxyribonucleic acid, ribonucleic acid, and miR, which
might be transferred to target cells (52). In the era of DM,
the available studies provide promising results for the role of
MPs, but currently limited to the risk of DM complications.
Thus, Tsimerman et al. (53) investigated the role of MPs in
DM vascular complications. The authors characterized the
cell origin and pro-coagulant proﬁles of MPs obtained from
healthy and DM subjects with CAD and DM-related
complications. They demonstrated that MP characteristics
are associated with the type of vascular complication and
might serve as a biomarker for the pro-coagulant state and
vascular pathology in patients with DM. In addition to these
ﬁnding it was shown (54) that EMP (CD31þ/CD42b-,
CD31þ/AVþ) levels were higher in patients with macro-
angiopathy than in patients with microangiopathy and no
complications. Endothelial MP level was also related to
macroangiopathy in DM patients. Moreover, plasma EMPs
have been associated with presence of hypertension and
arterial stiffness in patients with DM (55), whereas another
study has suggested that EMPs could be used as a surrogate
marker of unstable plaques and might help to improve
cardiovascular prediction in DM patients at intermediaterisk (on the basis of the association between plasma EMP-
CD144þ and coronary noncalciﬁed plaques) (56).
Current Effective Therapeutic Approaches
Targeting the “Diabetic” Vascular Function
Several therapeutic strategies might exert favorable effects
(Table 2) on the vasculature of diabetic patients, such as
insulin analogues, antihypertensive agents, statins, and
hypoglycemic agents, whereas in spite of the prominent role
of oxidative stress in diabetes, antioxidant therapy had no
beneﬁt in large randomized trials.
Hypoglycemic agents. Ersoy et al. (57) examined, among
others, PAI-1 and vascular endothelial growth factor levels
in obese diabetic patients who received metformin. After
a 12-week treatment the aforementioned biomarkers were
signiﬁcantly decreased. Additionally, in patients with T2D
who received metformin for 16 weeks, VCAM-1, ICAM-1,
PAI-1, soluble E-selectin, and vWF were signiﬁcantly
downregulated, whereas markers of inﬂammation remained
unaffected (58). After 6 months in long-acting insulin
analogues either insulin glargine or detemir signiﬁcantly
improved biomarkers of endothelial function (ICAM-1,
VCAM-1, E-selectin) as well as levels of EPCs (59),
whereas high doses of insulin for 12 months signiﬁcantly
reduced ﬁbrinogen, vWF, PAI-1, and thrombomodulin
(60). At this point, it is very important to discuss the
association of insulin and inﬂammation, because it is much-
debated, giving attention to the recent hypothesis for the
potential anti-inﬂammatory role of insulin. Thus, Dandona
et al. (61) investigated whether insulin reduces the magni-
tude of oxidative, nitrosative, and inﬂammatory stress and
tissue damage responses induced by endotoxin (lipopoly-
saccharide [LPS]). For this purpose, the authors recruited
healthy subjects who received intravenous injection with
LPS, along with others who received infusion with insulin in
addition to the LPS injection. The concomitant infusion of
insulin resulted in a signiﬁcant reduction, considering the
already known effects of LPS injection, in ROS generation
and the total prevention of the increase in thiobarbituric
acid–reacting substances, NO metabolites, and FFAs
concentrations. These effects were related to a signiﬁcant
reduction in the magnitude of increase in macrophage
migration inhibition factor, myoglobin, and visfatin levels
(independent of glucose levels). By contrast, insulin was
unable to prevent or reduce the magnitude of increase of
speciﬁc pro-inﬂammatory cytokines, raising further ques-
tions about the effect of more prolonged infusions and
higher doses of insulin.
Statins. A prospective double-blind trial investigating the
effect of atorvastatin in endothelial function of diabetic
persons has suggested that markers of endothelial function as
well as markers of inﬂammation were signiﬁcantly improved
after a 12-week treatment of atorvastatin (62). Additionally,
90 days of simvastatin resulted in amelioration of TNF-a,
CRP, and several types of ILs (IL-6, IL-2, IL-1b), which
Table 2 Agents Interfering With Endothelial Dysfunction in Diabetes Mellitus
First Author
(Ref. #) Population Treatment
Effect on Endothelial Function and/or
Inﬂammation p Value
De Jager
et al. (58)
390 patients with T2D
(30–80 yrs)
Metformin vs.
placebo
vWF, VCAMI-1, E-selectin, andPAI-1
reduced but CRP, ICAM-1 remain
unchanged
Within reference values
Jankovec
et al. (60)
13 obese patients with
T2D
Long-term insulin
pump
Thrombomodulin, PAI-1, vWF
reduced
<0.01
Economides
et al. (62)
Patients with T2D vs.
subjects at risk for T2D
Atorvastatin FMD improved in both groups, CRP
and TNF-a decreased at the at-
risk group
<0.05
Tehrani et al.
(65)
20 patients with T1D and
dyslipidemia
Placebo vs.
atorvastatin
p-selectin, tissue factor decreased,
PAI-1, hsCRP, ﬁbrinogen
unchanged in atorvastatin group
Within reference values
Neri et al.
(66)
46 patients with T2D, 46
patients with IGT, and
46 healthy individuals
Antioxidant
supplementation
(Vit C, Vit E, N-
acetylcysteine)
VCAM-1, vWF, ET-1, and oxidants
reduced, NO increased
<0.05
Schrametal.
(70)
70 hypertensive with T2D Hydrochlorothiazide
vs. candesartan vs.
lisinopril
VCAM-1 and ICAM-1 reduced, CRP
and vWF unchanged in all
groups
Within reference values
Beisswenger
et al. (72)
45 patients with T2D Prandial þ basal
insulin vs. basal
insulin
TNF-a, IL-6, hsCRP more
attenuated in prandial þ basal
insulin group
<0.01,
<0.01, and <0.001,
respectively
Tousoulis
et al. (73)
35 patients with newly
diagnosed T2D
MET vs. MET þ
atorvastatin
TNF-a reduced in MET þ
atorvastatin group
<0.05
Bellia et al.
(74)
29 patients with T2D with
mild untreated
dyslipidemia
Rosuvastatin vs.
simvastatin
FMD improved in the simvastatin
group, no changes in CRP
<0.01
Aversa et al.
(75)
20 patients with T2D
without erectile
dysfunction
Sildenaﬁl FMD increased, ET-1, CRP, IL-6,
VCAM-1, ICAM-1 reduced
0.01
Bank et al.
(76)
34 patients with T2D and
hypertension
Carvedilol vs.
metoprolol
FMD improved more in carvedilol
group
<0.001
Martinaetal.
(77)
24 male patients with
T2D and hypertension
L-arginine þ N-
acetylcysteine vs.
placebo
CRP, ICAM-1, VCAM-1, PAI-1
reduced
<0.05, <0.05, <0.01,
and <0.05,
respectively
Chakraborty
et al. (78)
208 patients with T2D Metformin vs.
placebo
CRP decreased <0.05
Karagiannis
et al. (79)
1,170 subjects with T2D PIO monotherapy vs.
PIO combined with
other oral anti-
diabetic drugs
hsCRP reduced <0.01
Pop-Busui
et al. (80)
27 subjects with T2D Rosiglitazone vs.
glyburide
hsCRP and vWFag reduced and
adiponectin increased in
rosiglitazone group
<0.03 and <0.05,
respectively
Haffner et al.
(81)
Patients with T2D Rosiglitazone vs.
placebo
CRP reduced <0.01
ACE ¼ angiotensin converting enzyme; CRP ¼ C-reactive protein; FMD ¼ ﬂow-mediated dilation; hsCRP ¼ high-sensitivity C-reactive protein; IGT ¼ impaired glucose tolerance; MET ¼ metformin; NO ¼ nitric
oxide; PIO ¼ pioglitazone; T1D ¼ type 1 diabetes mellitus; T2D ¼ type 2 diabetes mellitus; Vit ¼ vitamin; other abbreviations as in Table 1.
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673supports the aforementioned scenario, with regard to the
effect of statins on endothelial function (63). By contrast,
several conﬂicting studies have found no important im-
provement of either endothelial function or systemic inﬂam-
mation in diabetic persons treated with statins (64,65).
Antioxidants. A single-blind study recently enrolled
patients with T2D and examined the variance of certain
circulating markers after 15 days of antioxidants. Actually,
plasma levels of oxidants as well as biomarkers of endothelial
dysfunction (vWF, VCAM-1, enthothiline-1, NO) were
signiﬁcantly decreased (66). In addition, Haidara et al. (67),
in a diabetic rat model using alpha-tocopherol and vitamin
C, have shown that administration of antioxidantssigniﬁcantly decreased vWF, plasma soluble thrombomo-
dulin, and ﬁbrinogen. However, the protective effect of
antioxidants on vascular endothelium is still unidentiﬁed.
Renin-angiotensin system-related agents. Wago et al.
(68) examined the endothelial function and systemic
inﬂammation of subjects under the inﬂuence of telmisartan.
The FMD signiﬁcantly increased after a 12-month treat-
ment with telmisartan, whereas adiponectin and hsCRP
levels decreased; Flammer et al. (69) conﬁrmed these ﬁnd-
ings. After 4-week treatment with losartan, FMD signiﬁ-
cantly increased and isoprostane as a marker of oxidative
stress reduced, whereas CRP levels remained unaffected.
In addition, a double-blind study (70) observed that
Table 3 Important Biomarkers in Diabetes Mellitus
Biomarker Diabetes-Related Characteristics Most Reliable Methods
CRP (hsCRP) Increases rapidly, long rising periods, stability in plasma
Attenuates NO production
Decreases endothelial NO synthase
Triggers oxidation of low-density lipoprotein cholesterol
Induces PAI-1expression
Stimulates the release of matrix metalloproteinase-1
Activates macrophages to secrete tissue factor
Upregulates the expression of adhesion molecules in endothelial cells
Ultrasensitive solid-phase ELISAs
Immunoturbidimetric CRP assays
Immunonephelometry (laser nephelometry)
TNF-a Growth stimulating properties and growth inhibitory processes
self regulatory properties
Cytokines triggering
Inﬂammation and apoptosis
Expressed in cells such as: B-cells, T-cells, macrophages, monocytes, mast cells,
neutrophils and adipocytes
Enzyme-linked immunosorbent
Assays (ELISA)
IL-6 Affects extracellular matrix dynamics at mesangial and podocyte levels
Stimulates mesangial cell proliferation
Increases ﬁbronectin expression
Enhances endothelial permeability
Induces the production of adrenocorticotropin
Affects insulin sensitivity probably mediated by adenosine monophosphate-
activated protein kinase
Affects glucose homeostasis and metabolism directly and indirectly by action
on skeletal muscle cells, adipocytes, hepatocytes, pancreatic cells, and
neuroendocrine cells.
ELISAs
ICAM-1 Promotes the recruitment of mononuclear cells in diabetic glomeruli
Role in glomerular hyper-ﬁltration
Interactions of lymphocyte function-associated antigen-1
Binds with the site 117–133 of the ﬁbrinogen gamma chain
Leads to changes through the protein kinase C pathway, cAMP, phospholipase A2,
Caþ2 and proteosomes (extracellular signal transportation)
ELISAs
Flow cytometry
VCAM-1 Interacts with secreted protein acidic and rich in cysteine
Interacts with VLA-4
ELISAs
Flow cytometry
Fibrinogen Lower platelet inhibition
Interacts with ICAM-1
Automated clotting rate assays
Immunoassays (ELISA or nephelometric)
Automated immunoassays of total ﬁbrinogen
The Clauss ﬁbrinogen assay (on the basis of the
thrombin
clotting time)
Endothelial microparticles Thrombosis, cell inﬂammation, angiogenesis and cell-to-cell communication
Apoptosis
Factor XI-dependent pro-coagulant properties
Impaired no release
Flow cytometry
miRs Affect pancreatic b cells and insulin-target tissues
Interaction with TGF-beta
Affect insulin secretion
Real-time qPCR
Microarrays
RNA sequencing
Northern blot
In situ hybridization
Characteristics and measuring methods.
CAþ2 ¼ calcium doubly charged positive ion; cAMP ¼ cyclic adenosine monophosphate; ELISA ¼ enzyme-linked immunosorbent assay; miR¼micro-ribonucleic acid; PAI ¼ plasminogen activator inhibitor;
qPCR ¼ quantitative polymerase chain reaction; RNA ¼ ribonucleic acid; TGF ¼ transforming growth factor; VLA ¼ very late antigen; other abbreviations as in Tables 1 and 2.
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or lisinopril reduced VCAM-1 and ICAM-1, yet CRP and
vWF remain unchanged. We recently found that perindopril
signiﬁcantly improved endothelial function in diabetic
patients (71).Conclusions
The association between DM and vascular dysfunction is
under continuous investigation, and several circulating
biomarkers have been proposed as indicators of endothelial
dysfunction. Important biomarkers of the vasculature arerelated to endothelial function, inﬂammatory and coagulation
processes, and oxidative stress. These biomarkers could
explain the different pathophysiological aspects in patients
with DM and, along with the newly investigated biomarkers,
could provide useful guidelines for the treatment of these
patients.Reprint requests and correspondence: Dr. Dimitris Tousoulis,
Athens University Medical School, Hippokration Hospital, Vasi-
lisis Soﬁas 114, 115 28 Athens, Greece. E-mail: drtousoulis@
hotmail.com.
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